back to top
- Bring Novel Agents to the Fore in B-ALL: Adding Inotuzumab to Pediatric-Inspired Regimens for AYAsOctober 10, 2018 | November-December 2018, Volume 15, Issue 6
Drs. Luskin, DeAngelo, and Kim review a study that tests the clinical efficacy of combining an adolescent and young adult chemotherapy regimen with a novel antibody in the treatment of B-cell acute lymphoblastic leukemia.
- Circulating Tumor DNA in Lymphoma Monitoring: Fantasy, Fad, or Fact?September 04, 2018 | September-October 2018, Volume 15, Issue 5
Dr. Kim discusses a study that showcases the utility of circulating tumor DNA monitoring in classic Hodgkin lymphoma.
- The Usual Suspects Aren't Always the Bad Guys! Molecular MRD Comes of Age in AMLJuly 13, 2018 | July-August 2018, Volume 15, Issue 4
Dr. Kim discusses a study that demonstrates the relevance of molecular minimal residual disease by next-generation sequencing in acute myeloid leukemia.
- BETting on Targeted Therapy for ASXL1-mutated Myeloid NeoplasmsApril 26, 2018 | May-June 2018, Volume 15, Issue 3
Dr. Kim discusses a study that shows a critical link between ASXL1 truncation mutations and a novel therapeutic avenue employing BET bromodomain inhibitors through their demonstration of gain of altered ASXL1 function.
- A Real Nose-PincherApril 23, 2018 | May-June 2018, Volume 15, Issue 3
In this Image Challenge, Dr. Li and Dr. Kim present two peripheral blood smears and a bone marrow biopsy you can use to determine the cause of a patient's neutropenia.
- Surround and Protect! Expression of PD-L1 on Tumor-Associated Macrophages in Classic Hodgkin LymphomaFebruary 27, 2018 | March-April 2018, Volume 15, Issue 2
Dr. Kim looks at two studies that reaffirm the association between high macrophage counts and poor response to several traditional chemotherapy regimens, and remarkable responses to PD-L1-directed immunotherapy in relapsed/refractory cHL.
Dr. Kim is Associate Professor of Pathology at Harvard Medical School/Brigham and Women's Hospital. Her research program focuses on the study of normal and aberrant hematopoiesis, specifically the study of hematolymphoid malignancies.
Harvard Medical School; Brigham and Women's Hospital